Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children-Reference-Cited by-同舟云学术

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

Published:2022-01-25 Issue:2 Volume:7 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Gordon Oren^ORCID,Brosnan Mary Katherine^ORCID,Yoon Steve,Jung Dawoon^ORCID,Littlefield Kirsten^ORCID,Ganesan Abhinaya,Caputo Christopher A.,Li Maggie^ORCID,Morgenlander William R.^ORCID,Henson Stephanie N.,Ordonez Alvaro A.^ORCID,De Jesus Patricia,Tucker Elizabeth W.^ORCID,Peart Akindele Nadine,Ma Zexu^ORCID,Wilson Jo^ORCID,Ruiz-Bedoya Camilo A.^ORCID,Younger M. Elizabeth M.,Bloch Evan M.^ORCID,Shoham Shmuel,Sullivan David^ORCID,Tobian Aaron A.R.,Cooke Kenneth R.,Larman Ben,Gobburu Jogarao V.S.^ORCID,Casadevall Arturo^ORCID,Pekosz Andrew^ORCID,Lederman Howard M.,Klein Sabra L.^ORCID,Jain Sanjay K.^ORCID

Funder

The State of Maryland

Bloomberg Philanthropies

National Institute of Health

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/151518/files/pdf

Reference37 articles.

1. The convalescent sera option for containing COVID-19